Empagliflozin and progression of kidney disease in type 2 diabetes

Medicine and Dentistry

• Empagliflozin 100%
• Placebo 90%
• Nephropathy 45%
• Patient 36%
• Patient with Type 2 Diabetes 27%
• Inpatient 27%
• Cardiovascular System 18%
• Serum 18%
• Creatinine 18%
• Renal Replacement Therapy 18%
• Albuminuria 18%
• Hazard Ratio 9%
• Glomerular Filtration Rate 9%
• Maturity Onset Diabetes of the Young 9%
• Cardiovascular Disease 9%
• Cardiovascular Risk 9%
• Adverse Event 9%
• Kidney Function 9%
• Body Surface 9%
• Sodium Glucose Cotransporter 2 Inhibitor 9%
• Relative Risk Reduction 9%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 9%
• Analysis 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Empagliflozin 100%
• Kidney Disease 45%
• Albuminuria 18%
• Creatinine 18%
• Adverse Event 9%
• Non Insulin Dependent Diabetes Mellitus 9%
• Diabetes Mellitus 9%
• Cardiovascular Risk 9%
• Sodium Glucose Cotransporter 2 Inhibitor 9%
• Macroalbuminuria 9%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 9%
• Death 9%